Know Your Customer Better Than They Know Themselves: Value Proposition, Segmentation, Targeting, and Positioning in Life Sciences
This is the second post in a five-part series on life sciences commercialization strategy — What 19 Product Launches Taught Me. Post 1 — Read the anchor post first for the full context.
The value proposition is not a statement. It is a commercial hypothesis.
That distinction matters more than it appears. A statement is written once and filed. A hypothesis is tested, refined, and either confirmed or revised by the evidence the market returns. Organizations that treat the value proposition as a statement produce marketing materials. Organizations that treat it as a hypothesis produce commercial intelligence — and the commercial intelligence is what actually drives adoption.
The structure of a well-formed value proposition is deceptively simple:
For [target customer] who needs [benefits desired], [product/offering] provides [benefits provided]. Unlike [competitive offering], [product/offering] provides [point of differentiation].
Five elements. Every one of them must be specific. If any element is vague — if the target customer is described in generalities, if the benefits desired are assumed rather than investigated, if the point of differentiation is a claim the competitor could make with equal legitimacy — the value proposition has not yet been written. It has been drafted.
The discipline of making each element specific is not a writing exercise. It is a research exercise. It requires knowing the customer's decision-making process, the competitive landscape from the customer's perspective, and the specific dimension on which the product creates differentiated value. That knowledge comes from segmentation, targeting, and positioning — in that order, and iteratively, not sequentially.
The value proposition is a commercial hypothesis. Its specificity is a measure of how well the organization actually knows the customer it is trying to reach.
Segmentation: Homogeneous Within, Heterogeneous Between
Before the value proposition can be specific, the market must be understood as a set of distinct segments rather than a single undifferentiated audience. The marketing concept's foundational assumption — that consumers have varying needs, that markets are therefore composed of groups with different needs, behaviors, and decision-making processes — is the premise that makes targeting possible and positioning meaningful.
The operating principle of effective segmentation is expressed in two terms: homogeneous within, heterogeneous between. Each segment must be internally similar — similar enough that a single value proposition, a single media strategy, and a single price point produce consistent behavior within the group. Each segment must be distinct from other segments — different enough that what works for one group would be meaningfully less effective for another.
Data and technology have transformed the precision with which this principle can be applied. Geographic, behavioral, psychographic, and demographic data — available at granularity that was not operationally accessible a decade ago — allow segmentation analyses that identify clusters of customers who are multi-dimensionally similar in ways that predict commercial response. The competitive advantage of identifying those clusters before a competitor does is significant and compounds over time.
Five criteria determine whether a segment is worth pursuing. In practice, these are less a checklist than a stress test — a way of identifying where the commercial investment is likely to underperform before the organization commits to it:
Measurable — the segment's size, purchasing power, and defining characteristics can be quantified well enough to forecast demand and justify investment. If a segment cannot be measured, its commercial potential cannot be evaluated.
Substantial — the segment is large enough — or concentrated enough in high-value accounts — to justify the resources required to reach and serve it. Size is not the only measure of substance; willingness to pay and strategic importance matter equally.
Accessible — the segment can be reached and served through the organization's existing or buildable capabilities. A segment that is measurable and substantial but inaccessible through the organization's channel infrastructure or sales force design is a theoretical opportunity, not a commercial one.
Differentiable — the segment responds differently from other segments to different elements of the marketing mix. If a segment cannot be distinguished by its response to a specific value proposition, medium, or price point, it does not function as a distinct segment.
Actionable — the organization can develop effective programs to attract and serve the segment, given its current or achievable capabilities, resources, and competitive position. Actionability is the bridge between segmentation as analysis and segmentation as commercial strategy.
The operational question that underlies all five criteria is a threshold question: does the organization have the means, the resources, and the core competencies to serve this segment profitably? Can the segment spend enough — or generate enough downstream value — to make the investment economically justified relative to competitive alternatives? Answering those questions honestly before committing resources is the difference between segmentation as strategic discipline and segmentation as aspirational thinking.
Targeting: The Decision That Commits the Organization
Segmentation produces options. Targeting makes the commitment.
The targeting decision — which segments to pursue, in what sequence, with what level of resource investment — is one of the most consequential strategic choices in a product launch. It is also one of the most commonly under-examined, because organizations tend to pursue the largest available segment rather than the segment where their specific capability creates the most differentiated value.
The right target is not the largest segment. It is the segment where the intersection of the product's differentiated benefit and the customer's most acute need produces the most compelling case for behavioral change — and where the organization's commercial infrastructure can reach, engage, and convert that customer more effectively than any competitor.
In practice, targeting decisions in life sciences are constrained by three factors that must be assessed honestly before the commercial strategy is finalized: the organization's operational capacity to serve the segment at scale, the segment's economic profile relative to the cost of reaching it, and the competitive landscape within the segment — specifically, whether a competitor has already established a relationship with the segment's most influential decision-makers that would require displacing rather than simply out-maneuvering.
Optimization across these constraints — identifying the cluster of customers within a broader target market where multi-dimensional similarity predicts the highest commercial return — is where modern data and technology create the most significant competitive advantage. The organization that identifies the right cluster before the competitor does, and builds the commercial infrastructure around it before the competitor can respond, establishes a first-mover advantage in that segment that takes years to erode.
The right target is not the largest segment. It is the segment where the organization's specific capability produces the most differentiated value for the most acutely felt need.
Positioning: The Distinct Image in the Mind
Positioning is not where the product ranks on a competitive matrix. It is the distinct image the product occupies in the minds of target customers — defined relative to every alternative those customers have access to. That image is shaped partly by what the organization communicates and partly by what the customer observes, experiences, and hears from peers. In a market where social influence and peer recommendation carry as much weight as promotional messaging, the organization's control over that image is partial at best.
Three conditions are required for positioning to be meaningful: a clearly defined customer whose mind the organization is trying to occupy, a set of points of parity that establish the product's competitive legitimacy, and points of differentiation that are meaningful to that customer and not claimed with equal force by any competitor.
Points of Parity are the attributes necessary for a product to compete in a category — the conditions that must be met before differentiation is even possible. A product that fails to establish parity on the category's defining dimensions cannot be positioned effectively, because the customer's first question — does this product meet the basic standard? — remains unanswered. In life sciences, clinical evidence of efficacy and safety is typically the threshold point of parity. Commercial positioning cannot substitute for it.
Points of Differentiation are the attributes or benefits closely associated with the product that are not associated with competitive alternatives — and that matter to the specific customer the organization is targeting. The test for a genuine point of differentiation is two-sided: it must be meaningful to the customer, and it must be differentiated from the competitor. A claim that the competitor can make with equal legitimacy is a point of parity, not a point of differentiation, regardless of how the organization communicates it.
Perceptual mapping provides the empirical grounding for positioning decisions. A perceptual map charts how target customers actually perceive competing products across the dimensions that matter most to their purchasing decisions — and the gap between where the organization believes its product sits and where customers actually place it is one of the most important intelligence gaps to close before launch. The map reveals competitors the organization had not identified, gaps in the market the organization had not anticipated, and positioning vulnerabilities the competitor will exploit if the organization does not address them first.
Positioning can be built around multiple dimensions: price, quality, brand image, specific customer benefits, competitive comparisons, or portfolio positioning. The most durable positions in life sciences are built around a specific patient need — the most acute, most underserved, most unambiguously real unmet need in the target population — because that position is the hardest for a competitor to replicate without changing their product, their clinical evidence, or both.
Why STP Is a Cycle, Not a Sequence
The conventional presentation of segmentation, targeting, and positioning as sequential steps — segment first, then target, then position — understates how these three activities actually interact in commercial practice.
The value proposition informs segmentation: the claim the organization can most credibly make about its product's differentiated benefit is the hypothesis that segmentation must test. Segmentation constraints reshape the value proposition: a segment that is theoretically ideal but operationally inaccessible forces the organization to revise the proposition for the segment it can actually reach. Targeting decisions force specificity into both: the commitment to a specific segment requires a specific proposition that is calibrated to that segment's specific decision-making process. Positioning tests all three against the competitive reality the customer actually perceives — and the perceptual map frequently reveals that the customer's competitive frame is different from the organization's competitive frame, which requires revising all three.
Organizations that complete this cycle once — before launch — treat it as a one-time exercise. Organizations that run it continuously — updating segmentation as new behavioral data surfaces, revising positioning as the competitive landscape shifts, refining the value proposition as market access conditions evolve — treat it as a commercial capability. That capability compounds across a product's lifecycle in ways that a one-time segmentation exercise cannot.
What nineteen launches across five therapy sectors consistently showed: the organizations that invested in the continuous cycle of segmentation, targeting, and positioning — that treated each as a living hypothesis rather than a completed deliverable — consistently outperformed their competitors at launch and retained that advantage through the product's commercial maturity. The organizations that completed the cycle once and moved on to execution found themselves correcting course during the launch window rather than compounding the advantage they had built.
Segmentation, targeting, and positioning are not deliverables. They are a continuous intelligence cycle. The organizations that understand this treat them as a capability. The capability compounds.
In This Series
Post 1: What 19 Product Launches Taught Me: A Field Guide to Commercial Viability
Post 2: Know Your Customer Better Than They Know Themselves — You are here.
